TY - JOUR
T1 - Reliability and Construct Validity of the Physician's Global Assessment of Lung Disease in Systemic Juvenile Idiopathic Arthritis–Associated Lung Disease
AU - for the PGALD Validation Consortium Investigators
AU - Rife, Eileen
AU - Zhai, Guihua
AU - Altaye, Mekibib
AU - Andringa, Jennifer
AU - Brunner, Hermine I.
AU - Canna, Scott
AU - Henderson, Lauren A.
AU - Kimura, Yukiko
AU - Lieberman, Scott M.
AU - Riskalla, Mona
AU - Towe, Christopher
AU - Vogel, Tiphanie
AU - Wobma, Holly
AU - Schulert, Grant
AU - Aziz, Rabheh Abdul
AU - Angeles-Han, Sheila
AU - Baszis, Kevin
AU - Behrens, Edward
AU - Brunner, Hermine I.
AU - Burg, Gregory
AU - Canna, Scott
AU - Casey, Alicia
AU - Clark, Matthew
AU - Co, Dominic
AU - Collins, Kathleen
AU - Cron, Randy
AU - DeGuzman, Marietta
AU - Dedeoglu, Fatma
AU - Deterding, Robin
AU - Eberhard, Barbara
AU - Green, Deanna
AU - Hahn, Timothy
AU - Hinds, Daniel M.
AU - Hobday, Patricia
AU - Hong, Sandy
AU - Hersh, Aimee
AU - Huggins, Jennifer
AU - Kimura, Yukiko
AU - Kim, Susan
AU - Klein-Gitelman, Marisa
AU - Lovell, Daniel
AU - Lu, Patricia
AU - Mannion, Melissa
AU - Neely, Jessica
AU - O'Connor, Michael
AU - Onel, Karen
AU - Orandi, Amir
AU - Ramirez, Andrea
AU - Reinhard, Adam
AU - Riskalla, Mona
N1 - Publisher Copyright:
© 2026 The Author(s). ACR Open Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology.
PY - 2026/3
Y1 - 2026/3
N2 - Objective: The physician global assessment of lung disease (PGALD) is a recently proposed disease activity measure for patients with systemic juvenile idiopathic arthritis–associated lung disease (SJIA-LD). This study evaluates the reliability and construct validity of the PGALD. Methods: Fifty-seven pediatric rheumatologists and pulmonologists with experience caring for children with SJIA-LD were invited to rate 20 clinical vignettes using the PGALD, a 10-point Likert scale (0 = inactive SJIA-LD; 10 = highly active SJIA-LD). Raters were also asked to rate a subset of eight repeat vignettes. Interrater and intrarater reliability were assessed using intraclass correlation coefficients (ICCs), whereas SJIA-LD features influencing PGALD ratings were assessed using univariate analysis. Results: The ICC for all raters was 0.68 (95% confidence interval [CI] 0.54–0.82), indicating moderate to good interrater reliability. The retest ICC was 0.86 (95% CI 0.82–0.89), indicating good intrarater reliability. Factors associated with higher mean PGALD scores included the presence of crackles on auscultation (5.7 vs 2.9; P = 0.001), hypoxemia on pulse oximeter (5.6 vs 3.2; P = 0.01), current oxygen requirement (6.3 vs 3.5; P = 0.04), suggestive diagnostic imaging features (P ≤ 0.01), and three or more prescribed medications for SJIA-LD (P ≤ 0.01). Pulmonary function measures demonstrated significant negative correlations with PGALD scores: forced vital capacity (r = −0.71; P = 0.01), total lung capacity (r = −0.92; P = 0.01), and lung diffusion capacity (r = −0.97; P = 0.0002). Only C-reactive protein was weakly to moderately correlated with PGALD scores (r = 0.39; P = 0.09), whereas other laboratory markers (ferritin, interleukin 18, CXCL9, and sIL-2R) were not significantly correlated. Conclusions: The PGALD is a novel measure of SJIA-LD activity. Its initial validation suggests acceptable construct validity and reliability. Additional studies are needed to assess its responsiveness to change over time.
AB - Objective: The physician global assessment of lung disease (PGALD) is a recently proposed disease activity measure for patients with systemic juvenile idiopathic arthritis–associated lung disease (SJIA-LD). This study evaluates the reliability and construct validity of the PGALD. Methods: Fifty-seven pediatric rheumatologists and pulmonologists with experience caring for children with SJIA-LD were invited to rate 20 clinical vignettes using the PGALD, a 10-point Likert scale (0 = inactive SJIA-LD; 10 = highly active SJIA-LD). Raters were also asked to rate a subset of eight repeat vignettes. Interrater and intrarater reliability were assessed using intraclass correlation coefficients (ICCs), whereas SJIA-LD features influencing PGALD ratings were assessed using univariate analysis. Results: The ICC for all raters was 0.68 (95% confidence interval [CI] 0.54–0.82), indicating moderate to good interrater reliability. The retest ICC was 0.86 (95% CI 0.82–0.89), indicating good intrarater reliability. Factors associated with higher mean PGALD scores included the presence of crackles on auscultation (5.7 vs 2.9; P = 0.001), hypoxemia on pulse oximeter (5.6 vs 3.2; P = 0.01), current oxygen requirement (6.3 vs 3.5; P = 0.04), suggestive diagnostic imaging features (P ≤ 0.01), and three or more prescribed medications for SJIA-LD (P ≤ 0.01). Pulmonary function measures demonstrated significant negative correlations with PGALD scores: forced vital capacity (r = −0.71; P = 0.01), total lung capacity (r = −0.92; P = 0.01), and lung diffusion capacity (r = −0.97; P = 0.0002). Only C-reactive protein was weakly to moderately correlated with PGALD scores (r = 0.39; P = 0.09), whereas other laboratory markers (ferritin, interleukin 18, CXCL9, and sIL-2R) were not significantly correlated. Conclusions: The PGALD is a novel measure of SJIA-LD activity. Its initial validation suggests acceptable construct validity and reliability. Additional studies are needed to assess its responsiveness to change over time.
UR - https://www.scopus.com/pages/publications/105032760282
UR - https://www.scopus.com/pages/publications/105032760282#tab=citedBy
U2 - 10.1002/acr2.90006
DO - 10.1002/acr2.90006
M3 - Article
C2 - 41797235
AN - SCOPUS:105032760282
SN - 2578-5745
VL - 8
JO - ACR Open Rheumatology
JF - ACR Open Rheumatology
IS - 3
M1 - e90006
ER -